Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Linzagolix choline - Kissei Pharmaceutical/ObsEva

Next Previous
X
Search
Drug Profile

Linzagolix choline - Kissei Pharmaceutical/ObsEva

Alternative Names: BG-2109; KLH-2109; KLH-2109-choline; Linzagolix - Kissei Pharmaceutical/ObsEva; OBE-2109; OBE-2109-choline; Yselty

Latest Information Update: 10 Sep 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Kissei Pharmaceutical
  • Developer Bio Genuine; Kissei Pharmaceutical; ObsEva
  • Class 2 ring heterocyclic compounds; Amines; Antihormones; Antineoplastics; Carboxylic acids; Fluorobenzenes; Phenyl ethers; Pyrimidinones; Small molecules; Thiophenes
  • Mechanism of Action LHRH receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Registered Uterine leiomyoma
  • Phase III Endometriosis
  • Phase II Adenomyosis

Most Recent Events

  • 10 Sep 2024 Preregistration for Uterine leiomyoma in Taiwan (PO), (Kissei Pharmaceutical pipeline, September 2024)
  • 16 Jul 2024 Efficacy and adverse event data from the Phase-III clinical trials (KLH2301 and KLH2302) in Uterine leiomyoma released by Kissei Pharmaceutical
  • 14 Jul 2023 Phase-III clinical trials in Endometriosis (Adjuvant therapy) in China (PO) (NCT05894135)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top